💙 🔷 Not impressed by Big Tech in Q3? Explore these Blue Chip Bargains insteadUnlock them all

Zynex ranks 9th in Top 25 Medical Device Companies of 2024

EditorRachael Rajan
Published 2024-02-02, 09:46 a/m
© Reuters.
ZYXI
-

ENGLEWOOD, Colo. – Zynex , Inc. (NASDAQ: NASDAQ:ZYXI), a medical technology firm known for its non-invasive medical devices for pain management, rehabilitation, and patient monitoring, has been ranked 9th in The Healthcare Technology Report's Top 25 Medical Device Companies for 2024.

The company's CEO, Thomas Sandgaard said, "We're pleased to be included in the Top 25 Medical Device Companies for 2024. The Healthcare Technology Report's rankings include some of the largest and most innovative companies in the medical device space. We are proud to be included amongst our distinguished peers and believe these rankings are indicative of our outsized influence within the field. We look forward to the coming year as we continue to build on a successful 2023."

The company, established in 1996, has a portfolio that includes devices for pain management and rehabilitation, as well as non-invasive monitoring systems designed for hospital use.

The information in this article is based on a press release statement from the company.

InvestingPro Insights

In the wake of Zynex Inc.'s recent accolade, real-time data from InvestingPro shows a promising financial landscape for the company. Zynex's market capitalization stands at a robust $395.32 million, and with a Price/Earnings (P/E) ratio of 26.76, it reflects investor confidence in its earnings potential. Moreover, the company's revenue growth is impressive, with a 24.12% increase over the last twelve months as of Q1 2023, highlighting its strong market presence and potential for future expansion.

InvestingPro Tips indicate that Zynex's management has been actively bolstering shareholder value through aggressive share buybacks, and the company's cash flows can comfortably cover interest payments, suggesting a solid financial footing. Additionally, with liquid assets surpassing short-term obligations and a moderate level of debt, Zynex appears to be in a healthy liquidity position. These factors, coupled with a strong return over the last three months and predictions of profitability for the current year, underscore the company's robust financial health and operational efficiency.

For those looking to delve deeper into Zynex's financials, InvestingPro offers additional insights and metrics. With the special New Year sale, subscribers can now enjoy up to a 50% discount on InvestingPro subscriptions. To further sweeten the deal, use coupon code SFY24 for an additional 10% off a 2-year InvestingPro+ subscription, or SFY241 for an additional 10% off a 1-year subscription. With over 10 more InvestingPro Tips available for Zynex, subscribers can gain an even more comprehensive understanding of the company's financial health and market potential.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.